Report on assessment of techniques for benign prostatic hyperplasia released by EUnetHTA

14

May 2021

In late April 2021, the European Network for Health Technology Assessment, EUnetHTA, released a final report on the comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia. The evaluation was initiated in May 2020 in partnership with the Austrian Institute for HTA (AIHTA) and aimed to assess 21 minimally invasive surgical treatments for benign prostatic hyperplasia, either comparing minimally invasive treatments to each other or a standard surgical treatment such as transurethral resection of the prostate or open prostatectomy, in patients with an indication for surgical treatment.

The following conclusions are provided:

  • Few comparisons revealed statistically significant differences among functional outcomes, although the results in most cases are below the minimal clinically important difference threshold. The quality of the related evidence has been graded as low to very low, suggesting limited confidence in the estimates and that further research is likely to change these estimates;
  • The thulium laser enucleation of the prostate, transurethral incision of the prostate, aquablation, and prostatic urethral lift may provide some advantage over transurethral resection of the prostate in terms of the impact on sexual activity: evidence quality ranges from moderate (reduced impact on retrograde ejaculation for patients with small prostates undergoing transurethral incision of the prostate) to low or very low;
  • For safety concerns and side effects, some newer technologies may offer some advantage over transurethral resection of the prostate by reducing the transfusion requirement; a few technologies showed evidence of a positive or negative effect on urinary tract infection and incontinence;
  • Small sample sizes, biases in study design, heterogeneous populations, and an undefined primary hypothesis indicate the need for more and better research so that the advantages and disadvantages of all these technologies can be more clearly defined.

The full details in English can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

20

Jan 2023

In December 2022, the National Institute for Health and Care Research (NIHR) in England released six MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned laser therapy in diabetic macular oedema, EarlyCDT Lung blood test, video-assisted thoracoscopic or open lobectomy, urethral slings for stress urinary incontinence, placental growth factor (PlGF) and sFlt-1 tests, and photobiomodulation in the management of oral mucositis. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more

13

Jan 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in December 2022. Nine recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern the device used for neuromodulation, the device for the treatment of benign prostatic hyperplasia, orthopedic devices, as well as medical aids.

Read more

16

Sep 2022

In August 2022, the National Institute for Health and Care Research (NIHR) in England released two MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned the treatment of urodynamic stress incontinence after prostate surgery and closure techniques after surgery for colorectal cancer. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more

13

Sep 2022

In August 2022, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (aortic remodeling hybrid stent insertion during surgical repair of aortic dissection, bioresorbable stent implantation to treat coronary artery disease, superficial venous arterialization for chronic limb ischemia, transcutaneous electrical neuromuscular stimulation for urinary incontinence, focal resurfacing implants to treat articular cartilage damage in the knee), and three new Medtech Innovation Briefings (Stockholm3 for prostate cancer screening, contrast-enhanced spectral mammography, differential target multiplexed spinal cord stimulation). Also, two Medical Technologies Guidance and two Medtech-related clinical guidelines were updated.

Read more

29

Aug 2022

On July 27, 2022, the EUnetHTA 21 released the assessment framework for high-risk medical devices (MDs) and in-vitro-diagnostics (IVDs). The objective of this deliverable is to define the framework for Joint Clinical Assessments of high-risk MDs and IVDs with a view to fostering national uptake of the Joint Clinical Assessments reports early in the life cycle of a single technology.

Read more